Sourcing Established Human Embryonic Stem Cell Lines

Human Embryonic Stem Cells: The Practical Handbook

Volumn , Issue , 2007, Pages 11-24

  Stacey, Glyn ^a  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

Cell banks; Ethics; Human embryonic stem cell; Quality assurance; Quality control; Regulation; Sourcing

Indexed keywords

EID: 84889405986     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470511619.ch2     Document Type: Chapter

References (28)

1. Briske-Anderson MJ, JW Finley and SM Newman. (1997). The influence of culture passage number on morphology and physiological development of Caco-2 cells. Proc Soc Exp Biol Med 4: 248-257.
2. Christensen B, C Hansen, M Debiek-Rychter, J Kieler, S Ottensen and J Schmidt. (1993). Identity of tumourigenic uroepithelial cell lines and 'spontaneously' transformed sublines. Br J Can 68: 879-884.
3. Cobo F, GN Stacey, C Hunt, C Cabrera, A Nieto, R Montes, JL Cortes, P Catalina, A Barnie and A Concha. (2005). Microbiological control in stem cell banks: approaches to standardisation. Appl Microbiol Biotechnol 68: 456-66.
4. Coecke S, M Balls, G Bowe, J Davis, G Gstraunthaler, T Hartung, R Hay, O-W Merten, A Price, L Shechtman, GN Stacey and W Stokes. (2005). Guidance on good cell culture practice. A report of the second ECVAM Task Force on Good Cell Culture Practice, ATLA 33: 1-27.
5. Del Guidice RA and RS Gardella. (1984). Mycoplasma infection of cell culture: effects, incidence and detection, In: In vitro Monograph 5, Uses and standardisation of vertebrate cell cultures. Tissue Culture Association, Gaithersberg MD, USA, 1984, pp 104-115.
6. Doyle A and GN Stacey. (2000). Cell and cell line characterisation. In: Encyclopedia of Cell Technology. R Spier, ed. John Wiley & Sons, New York, pp 285-293.
7. Draper JS, C Pigott, JA Thomson and PA Andrews. (2002). Surface antigens of human embryonic stem cells: changes upon differentiation in culture. J Anat 200: 249-258.
8. Drexler HG, WG Dirks, Y Matsuo and RA MacLeod. (2003). False leukemia-lymphoma cell lines: an update on over 500 cell lines. Leukemia 17: 416-426.
9. European Medicines Evaluation Agency (1997) Note for guidance on quality of biotechnological products: viral safety evaluation of biotechnology products derived from cell lines of human or animal origin (CPMP/ICH/295/95). European Medicines Evaluation Agency, 7 Westferry Circus, Canary Wharf, London, E14 4HB UK. (http://www.eudra.org/emea.html).
10. European Pharmacopeia (2006b). European Pharmacopeia section 2.6.7 (Mycoplasma) (5th Edition). Maisonneuve SA, Sainte Ruffine.
11. Folmer O, M Black, W Hoeh, R Lutz and R Vrijenhoek. (1994). DNA primers for amplification of mitochondrial cytochrome c oxidase subunit I from diverse metazoan invertebrates. Mol Mar Biol Biotechnol 3: 294-299.
12. Hanson C and C Caisander. (2005). Human embryonic stem cells and chromosome stability. APMIS 113: 751-755.
13. Healy L, C Hunt, L Young and G Stacey. (2005). The UK Stem Cell Bank: Its role as a public research resource centre providing access to well-characterised seed stocks of human stem cell lines. Adv Drug Deliv Rev 57: 1981-1988.
14. Jeffreys AJ, V Wilson and S-L Thein. (1985). Individual specific fingerprints of human DNA. Nature 316: 76-79.
15. MacLeod RAF, WG Dirks, Y Matsuo, M Kaufman, H Milch and HG Drexler. (1999). Widespread intra-species cross-contamination of human tumour cell lines arising at source. Int J Cancer 83: 555-563.
16. McGarrity GI, H Kotani and GH Butler. (1993). Mycoplasma and tissue culture cells. In: Mycoplasmas: Molecular Biology and Pathogenesis. J Maniloff, ed. ASM Press, pp 445-454.
17. Nelson-Rees WA, DW Daniels and RR Flandermeyer. (1981). Cross-contamination of cells in culture. Science 212: 446-452.
18. Nicklas W, V Kraft and B Meyer. (1993). Contamination of transplantable tumour cell lines and monoclonal antibodies with rodent viruses. Lab Anim Sci 43: 296-300.
19. Rottem S and Y Naot. (1998). Subversion and exploitation of host cells by mycoplasma. Trends Microbiol 6: 436-440.
20. Stacey GN. (in press). Risk assessment of cell culture procedures. In: Medicines from Animal Cells. GN Stacey and J Davis, eds. John Wiley and Sons, Chichester, UK.
21. Stacey GN, ED Byrne and JR Hawkins. (2007). DNA Fingerprinting and characterisation of Animal Cell Lines, Chapter 4, In: Animal Cell Biotechnology Methods and Protocols, Second Edition, ED Ralf Portner, Humana Press, Totowa, NJ, pp 123-145.
22. Stacey GN, DA Tyrrel and A Doyle. (1998). Source materials. In: Safety in Cell and Tissues Culture, GN Stacey, PJ Hambleton and A Doyle, eds. Kluwer Academic Publishers, Dordrecht, Netherlands, pp 1-25.
23. Stacey GN, F Cobo, A Nieto, P Talavera, L Healy, A Concha. (2006). The development of 'feeder' cells for the preparation of clinical grade hES cell lines: challenges and solutions. J Biotechnol 125: 583-8.
24. Stacey GN and C Hunt. (2006). The UK Stem Cell Bank: a UK government funded International resource centre for stem cell research. Regen Med 1: 139-142.
25. Uphoff CC and HG Drexler. (2002). Comparative PCR analysis for detection of mycoplasma infections in continuous cell lines. In Vitro Cell Dev Biol Anim 38: 79-85.
26. US Food and Drugs Administration. (2005a). Title 21, Code of Federal Regulations, Volume 7, revised April 2005, CFR610.12 (Sterility). FDA, Department of Health and Human Services.
27. US Food and Drugs Administration. (2005b). Title 21, Code of Federal Regulations, Volume 7, revised April 2005, CFR610.30 (Test for Mycoplasma). FDA, Department of Health and Human Services.
28. Yu H, TJ Cook and PS Sinko. (1997). Evidence of diminished functional expression of intestinal transporters in Caco-2 monolayers at high passage. Pharm Res 14: 757-762.